Abstracts tagged "mouse model and salivary hypofunction"

Abstract Number: 661 • 2016 ACR/ARHP Annual Meeting
Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction
Magdalena Sroka¹, Indranil Biswas¹, Brian Shepherd¹, Dat C Truong², Harini Bagavant¹ and Umesh S Deshmukh¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma, Norman, OK
Background/Purpose: Circulating autoantibodies reactive against Ro52 are detected in the sera of 70% of patients with Sjögren’s syndrome (SS), and their presence has been associated…
Abstract Number: 1798 • 2014 ACR/ARHP Annual Meeting
Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for the Induction of Sjogren’s Syndrome-like Disease in Mice
Paulina Kaplonek¹, Barbara Szczerba², Nina Wolska¹, Paulina Rybakowska¹, Arkadiusz Klopocki¹, Paromita Dey³, Astrid Rasmussen⁴, Kimberly Hefner⁵, Stephen Young⁶, Donald U. Stone⁷, David M. Lewis⁶, Lida Radfar⁸, R. Hal Scofield⁴, Kathy Moser Sivils⁹, Harini Bagavant⁹ and Umesh Deshmukh⁹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Virginia, Charlottesville, VA, ³Department of Medicine, University of Virginia, Charlottesville, VA, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose . Autoantibodies reactive with Ro52 are present in almost 70% of Sjögren’s syndrome (SS) patients. This study was undertaken to investigate the role of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].